Nagoya University Pancreatic Tumor Board trial 08

Nagoya University Pancreatic Tumor Board trial 08 - NUPAT-08

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041200054

Enrollment

Registered

2020-10-22

Start date

2021-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally advanced pancreatic cancer

Interventions

Concurrent CRT group Patients will undergo chemotherapy with 100mg/m2 nab-PTX and 800 mg/m2 gemcitabine for 8 weeks. Concurrent radiotherapy will be also performed. After chemoradiotherapy, patients w

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Locally advanced pancreatic cancer 2.Age 20<= and <=79 3.Performance status 0-1

Exclusion criteria

Exclusion criteria: 1.distant metastasis 2.severe drug allergy 3.viable multiple primary cancer 4.gastrointestinal invasion 5.apparent infectious status 6.history of abdominal radiotherapy 7.pregnant or breastfeeding female

Design outcomes

Primary

Measure	Time frame
2-year survival rate	—

Secondary

Measure	Time frame
Recurrence free survival, overall survival, pathological tumor reduction according to Evans grade, Tumor response defined by RECIST, rate of completion of preoperative therapy, rate of adverse effect, surgical morbidity, early tumor shrinkage, time to treatment failure	—

Contacts

Public ContactHideki Takami

Nagoya University Graduate School of Medicine

takami.hideki.r7@f.mail.nagoya-u.ac.jp+81-52-744-2245

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026